Outcomes in BCG failure: Outcome from a single centre UK experience
Abstract Objective To describe real‐world outcomes of patients with BCG failure undergoing bladder‐sparing treatments (BSTs) vs radical cystectomy in the UK. Patients and Methods A single institution audit was conducted at a tertiary bladder cancer referral service (UCLH, London, UK). Patients with...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-05-01
|
| Series: | BJUI Compass |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/bco2.70025 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850109307432992768 |
|---|---|
| author | Elizabeth Day Rachel Aquilina Lazaros Tzelves Ashwin Sridhar Anthony Ta John Kelly Bernadett Szabados |
| author_facet | Elizabeth Day Rachel Aquilina Lazaros Tzelves Ashwin Sridhar Anthony Ta John Kelly Bernadett Szabados |
| author_sort | Elizabeth Day |
| collection | DOAJ |
| description | Abstract Objective To describe real‐world outcomes of patients with BCG failure undergoing bladder‐sparing treatments (BSTs) vs radical cystectomy in the UK. Patients and Methods A single institution audit was conducted at a tertiary bladder cancer referral service (UCLH, London, UK). Patients with BCG failure treated between January 2017 and September 2022 were included. BSTs included endoscopic surveillance, hyperthermic mitomycin and further BCG. The primary outcome was event free survival (EFS). Complete response (CR) rate and duration of response (DoR) were investigated in patients undergoing BST. The secondary outcomes were 3‐ and 5‐year cancer‐specific (CSS) and overall survival (OS). Results A total of 112 patients were included: 30% (34/112), 32% (36/112) and 27% (30/112) had BCG unresponsive, exposed and intolerant disease and 11% (12/112) had progressed to muscle invasive disease (MIBC). In the BCG unresponsive and exposed groups, 79% (27/34) and 72% (26/36) underwent RC, with the remaining receiving BSTs. Comparing RC vs BST in BCG unresponsive and exposed groups combined, there was a significantly poorer EFS in the BST group (p < 0.001); 35.3% (6/17) patients transitioned to second‐line BST due to recurrence or intolerance and a further 50% (3/6) transitioned a third line BST. There was no significant difference in CSS or OS rates. In BCG intolerance, the EFS rate was 90% as three patients experienced high‐grade recurrence and underwent RC. There were no cancer‐related deaths. In MIBC group, 5/12 presented with metastatic disease and 3‐ and 5‐year CSS rates was 66% and 0%. Conclusion This data reports real‐world practice in a UK centre. BSTs in BCG unresponsive and exposed disease are supported as an alternative to RC providing the increased risk of recurrence is accepted. Additionally, consideration of formal guidance supporting BST is needed in BCG intolerance, which appears to have an excellent outcome in a cohort managed with endoscopic surveillance. Upstaging to MIBC remains a poor prognostic factor and is key to improving survival outcomes in BCG failure. |
| format | Article |
| id | doaj-art-8fb0fea926af41579bdbf3ffcaad7d4c |
| institution | OA Journals |
| issn | 2688-4526 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | Wiley |
| record_format | Article |
| series | BJUI Compass |
| spelling | doaj-art-8fb0fea926af41579bdbf3ffcaad7d4c2025-08-20T02:38:06ZengWileyBJUI Compass2688-45262025-05-0165n/an/a10.1002/bco2.70025Outcomes in BCG failure: Outcome from a single centre UK experienceElizabeth Day0Rachel Aquilina1Lazaros Tzelves2Ashwin Sridhar3Anthony Ta4John Kelly5Bernadett Szabados6Department of Urology University College London Hospital NHS Foundation Trust London UKSchool of Medicine University College London London UK2nd Department of Urology Sismanogleio Hospital, National and Kapodistrian University of Athens GreeceDepartment of Urology University College London Hospital NHS Foundation Trust London UKDepartment of Urology St Vincent's Hospital Melbourne AustraliaDepartment of Urology University College London Hospital NHS Foundation Trust London UKDepartment of Urology University College London Hospital NHS Foundation Trust London UKAbstract Objective To describe real‐world outcomes of patients with BCG failure undergoing bladder‐sparing treatments (BSTs) vs radical cystectomy in the UK. Patients and Methods A single institution audit was conducted at a tertiary bladder cancer referral service (UCLH, London, UK). Patients with BCG failure treated between January 2017 and September 2022 were included. BSTs included endoscopic surveillance, hyperthermic mitomycin and further BCG. The primary outcome was event free survival (EFS). Complete response (CR) rate and duration of response (DoR) were investigated in patients undergoing BST. The secondary outcomes were 3‐ and 5‐year cancer‐specific (CSS) and overall survival (OS). Results A total of 112 patients were included: 30% (34/112), 32% (36/112) and 27% (30/112) had BCG unresponsive, exposed and intolerant disease and 11% (12/112) had progressed to muscle invasive disease (MIBC). In the BCG unresponsive and exposed groups, 79% (27/34) and 72% (26/36) underwent RC, with the remaining receiving BSTs. Comparing RC vs BST in BCG unresponsive and exposed groups combined, there was a significantly poorer EFS in the BST group (p < 0.001); 35.3% (6/17) patients transitioned to second‐line BST due to recurrence or intolerance and a further 50% (3/6) transitioned a third line BST. There was no significant difference in CSS or OS rates. In BCG intolerance, the EFS rate was 90% as three patients experienced high‐grade recurrence and underwent RC. There were no cancer‐related deaths. In MIBC group, 5/12 presented with metastatic disease and 3‐ and 5‐year CSS rates was 66% and 0%. Conclusion This data reports real‐world practice in a UK centre. BSTs in BCG unresponsive and exposed disease are supported as an alternative to RC providing the increased risk of recurrence is accepted. Additionally, consideration of formal guidance supporting BST is needed in BCG intolerance, which appears to have an excellent outcome in a cohort managed with endoscopic surveillance. Upstaging to MIBC remains a poor prognostic factor and is key to improving survival outcomes in BCG failure.https://doi.org/10.1002/bco2.70025BCG failurebladder cancerbladder sparing treatmentHyperthermic Mitomycinradical cystectomy |
| spellingShingle | Elizabeth Day Rachel Aquilina Lazaros Tzelves Ashwin Sridhar Anthony Ta John Kelly Bernadett Szabados Outcomes in BCG failure: Outcome from a single centre UK experience BJUI Compass BCG failure bladder cancer bladder sparing treatment Hyperthermic Mitomycin radical cystectomy |
| title | Outcomes in BCG failure: Outcome from a single centre UK experience |
| title_full | Outcomes in BCG failure: Outcome from a single centre UK experience |
| title_fullStr | Outcomes in BCG failure: Outcome from a single centre UK experience |
| title_full_unstemmed | Outcomes in BCG failure: Outcome from a single centre UK experience |
| title_short | Outcomes in BCG failure: Outcome from a single centre UK experience |
| title_sort | outcomes in bcg failure outcome from a single centre uk experience |
| topic | BCG failure bladder cancer bladder sparing treatment Hyperthermic Mitomycin radical cystectomy |
| url | https://doi.org/10.1002/bco2.70025 |
| work_keys_str_mv | AT elizabethday outcomesinbcgfailureoutcomefromasinglecentreukexperience AT rachelaquilina outcomesinbcgfailureoutcomefromasinglecentreukexperience AT lazarostzelves outcomesinbcgfailureoutcomefromasinglecentreukexperience AT ashwinsridhar outcomesinbcgfailureoutcomefromasinglecentreukexperience AT anthonyta outcomesinbcgfailureoutcomefromasinglecentreukexperience AT johnkelly outcomesinbcgfailureoutcomefromasinglecentreukexperience AT bernadettszabados outcomesinbcgfailureoutcomefromasinglecentreukexperience |